Novo Nordisk A/S $NVO Shares Sold by Quadrant Capital Group LLC

Posted by Brian Himes on Oct 22nd, 2026

Quadrant Capital Group LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 44.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,869 shares of the company’s stock after selling 51,643 shares during the period. Quadrant Capital Group LLC’s holdings in Novo Nordisk A/S were worth $2,431,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of NVO. Arrowstreet Capital Limited Partnership acquired a new stake in Novo Nordisk A/S during the 1st quarter worth about $287,660,000. State Street Corp increased its position in shares of Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock worth $284,565,000 after acquiring an additional 32,641 shares in the last quarter. Royal Bank of Canada increased its position in shares of Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after acquiring an additional 141,376 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after acquiring an additional 71,684 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Novo Nordisk A/S by 6.7% during the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock valued at $124,844,000 after acquiring an additional 213,443 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.6%

Shares of NYSE NVO opened at $39.10 on Thursday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The firm has a market capitalization of $174.58 billion, a PE ratio of 9.56, a PEG ratio of 1.34 and a beta of 0.76. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average price of $42.21 and a two-hundred day moving average price of $44.01.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. As a group, analysts predict that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. This represents a yield of 258.0%. Novo Nordisk A/S’s payout ratio is presently 20.05%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NVO shares. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, September 10th. DZ Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. BMO Capital Markets set a $40.00 price objective on shares of Novo Nordisk A/S and gave the stock a “market perform” rating in a research report on Monday, October 12th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Finally, Berenberg Bank restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $59.44.

View Our Latest Stock Report on Novo Nordisk A/S

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: CagriSema produced an average 25% reduction in body weight after 68 weeks among women with obesity or overweight in a late-stage analysis. The result strengthens the drug’s potential as a successor to Wegovy and could improve Novo’s long-term position in the expanding obesity-treatment market. Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Positive Sentiment: The CagriSema data prompted a recent rally as investors viewed the treatment’s efficacy as a potential catalyst for renewed growth. Regulatory submissions and further clinical progress could provide additional upside, although approval is not yet guaranteed. Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
Positive Sentiment: Novo expanded its 2026 share buyback, increasing its treasury-share stake to 1.2%. The program signals management’s confidence and may support earnings per share by reducing the number of shares outstanding. Novo Nordisk expands 2026 share buyback
Neutral Sentiment: Novo remains a major player in diabetes and obesity treatments, with additional pipeline projects and partnerships offering potential growth over the next decade. However, those benefits depend on successful trials, regulatory approvals, manufacturing investment, and commercialization. Where Will Novo Stock Be in 10 Years?
Negative Sentiment: Investors continue to assess rising competition from Eli Lilly and Viking Therapeutics, along with risks from drug-pricing pressure, intellectual-property challenges, and declining earnings estimates. These concerns help explain why the stock remains under pressure despite the promising CagriSema results. How Investors May Respond To Novo Nordisk Obesity Drug Competition

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.